<DOC>
	<DOCNO>NCT02102672</DOCNO>
	<brief_summary>Pulmonary artery hypertension ( PAH ) chronic progressive disease affect 15 person per million . Although current therapy improve disease prognosis , PAH still poor survival , median survival 2.8 year diagnosis . In last year new key element PAH pathogenesis discover , role metabolism disease onset progression . In fact , PAH pulmonary smooth muscle cell switch glycolytic phenotype resembles metabolism cancer cell . The investigator hypothesis `` fatty acid oxidation inhibition revert PAH adverse phenotype restore mitochondrial function morphology , decrease proliferation restore apoptosis susceptibility pulmonary smooth muscle cell ``</brief_summary>
	<brief_title>Trimetazidine Pulmonary Artery Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Trimetazidine</mesh_term>
	<criteria>PAH patient belong follow subgroup update Dana Point Classification Group 1 1 . Idiopathic PAH 2 . Heritable PAH 3 . Drug toxininduced PAH 4 . PAH associate connective tissue disease 5 . PAH associate congenital heart disease simple systemictopulmonary shunt least 1 year surgical repair 6 . PAH associate HIV infection Documented hemodynamic diagnosis PAH right ventricular catheterization perform time prior screening Signed informed consent Patients belong subgroup update Dana Point Classification Group I list inclusion criterion Patients belong group 25 updated Dana Point Classification Group Moderate severe chronic pulmonary obstructive disease Documented leave ventricular dysfunction Severe renal impairment ( Serum creatinine &gt; 2.5 mg/dL ) Patients receive receive investigational drug within 1 month baseline visit Acute chronic impairment ( dyspnea ) limit ability comply study requirement Psychotic , addictive disorder limit ability provide inform consent comply study requirement Life expectancy le 12 month Females lactate pregnant plan become pregnant study Known hypersensitivity excipients drug formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>